tirzepatide sublingual (13mg) Tirzepatide Oral vs Injection: Pros,

It has decades of randomized controlled trial data behind it and is widely regarded as the reference-standard topical retinoid against which newer molecules are measured

is a consultant for Entrinsic and Kallyope

Saxenda is a GLP-1 receptor agonist licensed for weight management in adults with BMI 30 kg/m or 27 kg/m with comorbidities Plateaus occur due to metabolic adaptation, reduced energy expenditure, dietary adherence decline, and hormonal changes during weight loss Treatment should be discontinued after 12 weeks on 3.0 mg if less than 5% initial body weight has been lost, per NICE guidance Accurate calorie tracking, increased protein intake, and progressive physical activity are evidence-based strategies to overcome plateaus Seek urgent medical attention for severe abdominal pain, gallbladder symptoms, or persistent vomiting which may indicate serious complications Table of Contents Understanding Weight Loss Plateaus on Saxenda Why Saxenda May Stop Working After Initial Success Evidence-Based Strategies to Restart Weight Loss on Saxenda When to Speak with Your GP About Your Saxenda Plateau Lifestyle Adjustments That Support Saxenda Effectiveness Scientific References Frequently Asked Questions Understanding Weight Loss Plateaus on Saxenda A weight loss plateau whilst taking Saxenda (liraglutide 3.0 mg) is a common and often frustrating experience

These insights can support a more informed conversation with your healthcare provider about expected response patterns and potential metabolic considerations

HOMA-IR was calculated as insulin mU/L glucose mM/22.5, and HOMA2-IR was calculated by a computerized algorithm